Yang J, Delara R, Magrina J, et al. - Researchers used the Mayo Clinic Cancer Registry to evaluate clinical features as well as survival of patients with primary vaginal cancer. This analysis involved 124 patients. Overall 39 patients had stage I disease, 44 had stage II, 20 had stage III, and 21 patients had stage IV. Overall 71% of tumors were squamous cell carcinoma. In stage I, II, III and IV, 5-year PFS was estimated to be 58.7%, 59.4%, 67.3% and 31.8%, respectively, and 5-year DSS was reported to be 84.3%, 73.7%, 78.7% and 26.5% respectively. In univariate analysis, the identified poor prognosticators were: advanced stage, tumor size > 4 cm, entire vaginal involvement, and lymph node metastasis. Findings demonstrated that vaginal cancer stage I and II was effectively treated with surgery or radiation, and that increased survival in stages III-IV was achieved by adding brachytherapy to external pelvic radiation.